Aprepitant for Postoperative Nausea and Vomiting
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using any medication that severely interacts with Aprepitant.
What data supports the effectiveness of the drug aprepitant for preventing postoperative nausea and vomiting?
Is aprepitant safe for humans?
How is the drug aprepitant unique for treating postoperative nausea and vomiting?
Aprepitant is unique because it works by blocking neurokinin-1 (NK-1) receptors, which is different from many other treatments that target serotonin receptors. It has been shown to provide better protection against vomiting and has a longer-lasting effect, reducing the need for additional medication after surgery.13478
What is the purpose of this trial?
This research trial will measure how useful Aprepitant is in preventing nausea and vomiting in children having surgery to correct scoliosis (curvature of the spine).
Research Team
Mathew Kiberd, MD
Principal Investigator
IWK Health Centre
Eligibility Criteria
This trial is for children aged 8-18 undergoing scoliosis surgery to correct spinal curvature. They must weigh over 40kg and have a spinal fusion involving at least six vertebral levels. It's not suitable for those who don't meet these specific surgical or age requirements.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Aprepitant or placebo to prevent postoperative nausea and vomiting during scoliosis surgery
Post-operative Monitoring
Participants are monitored for nausea, vomiting, and other adverse events post-surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Aprepitant
Find a Clinic Near You
Who Is Running the Clinical Trial?
IWK Health Centre
Lead Sponsor